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Abstract This double case report indicates that treatment
with intravenous immunoglobulins (IVIG) is effective in
patients with Sydenham chorea (SC). SC is a rare but
impressive clinical manifestation following streptococcal
infection. This movement disorder characterised by chorea,
emotional lability and muscle weakness, is one of the major
criteria of acute rheumatic fever. Treatment of SC is
typically limited to supportive care and palliative medica-
tions. Curative treatment is still in the experimental stage.
Recent research on patients with SC proved that antibodies
against the group A streptococcus cross-react with epitopes
of neurons in the basal ganglia, namely, intracellular tubulin
and extracellular lysoganglioside. Therefore, immune mod-
ulating therapy by means of prednisone, plasma exchange
and IVIG are mentioned in the literature as possible
effective treatment. Beneficial effect of IVIG has been
shown in several diseases with molecular mimicry as the
underlying pathophysiology. In this paper, we describe two
girls aged 11 and 13 years, respectively, who presented with
SC having severe disabilities in their daily live. We treated
both patients with IVIG 400 mg/kg/day for 5 days.
Treatment was tolerated well and had a pronounced positive
effect. Shortly after the drug was administered, all signs and
symptoms disappeared in both patients. Based upon these
patients, we highlight IVIG as a serious treatment option
for SC.
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Abbreviations
SC Sydenham chorea
ARF Acute rheumatic fever
IVIG Intravenous immunoglobulins
ESR Erythrocyte sedimentation rate
ASOT Antistreptolysin O titre
ABGA Anti-basal ganglia antibodies
Introduction
Sydenham chorea (SC), also known as St. Vitus dance and
chorea minor, is a rare but impressive clinical manifestation
following streptococcal infection. This movement disorder
characterised by chorea, emotional lability and muscle
weakness is one of the major criteria of acute rheumatic
fever (ARF) [24]. Chorea is observed in 18–36% of all
patients with ARF [3, 25, 29].
The incidence of ARF and SC reflects the adequacy of
preventive medical care in a community and has declined
dramatically in the Western world [9, 20]. However, chorea
is still a common manifestation of ARF in developing
countries, and a number of recent outbreaks in the USA
indicate the need for awareness of this disease [3, 25].
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The natural course of the illness varies widely. Com-
plaints can last for months to years, and 20–42% of the
patients have a relapse [8, 16]. Treatment of SC is
typically limited to supportive care and palliative medi-
cations. Curative treatment is still in the experimental
stage [4, 7, 30].
In this paper, we describe two patients with SC and
severe disabilities in daily life. Based upon the experience
with them, we advocate the use of intravenous immuno-
globulins (IVIG) as a treatment option for SC in view of the
latest insights in the pathophysiology of SC.
Patients
Patient number 1, an 11-year-old girl, presented at the adult
outpatient neurology department with involuntary move-
ments since several days, which she described as “My arms
hit and my legs kick while I do not want them to do so”.
Her parents expressed concern about garbled speech,
emotional lability and regressive behaviour. There were
no indications for recent infections. Especially, sore throat,
joint pain and fever were not noticed. However, she did
complain about general muscle weakness.
On physical examination, we saw a girl with a figure
fitting her age showing continual irregular, uncontrolled
movements of the upper and lower extremities and to
some extend also of the head and trunk. Her speech was
incomprehensive and, at rest, she made sucking and
swallowing movements. Coordination was intact, illustrat-
ed by the ability to catch a ball despite her chaotic
movements. There were no further neurological abnormal-
ities. Further examination revealed enlarged, painless
submandibular lymph nodes. There were no a clinical
signs of endocarditis.
Laboratory findings showed a normal complete blood
cell count, erythrocyte sedimentation rate (ESR) of 6 mm/
h (1–25 mm/h) and an antistreptolysin O titre (ASOT) of
800–1,600 IU/ml (<250 IU/ml). Rheumatoid factor and
anticardiolipin antibody were negative. In the throat culture,
performed several weeks after presentation, no pathogens
were isolated. Computed tomography of the brain did not
reveal any anatomical anomaly.
A penicillin course of treatment was given. Concerning
the SC, a policy of “wait and see” was followed because of
the well-known high number of patients who recover
spontaneously. However, after 2 months, her symptoms
had worsened, and she became wheelchair bound. Subse-
quently, she was referred to us.
Based upon analyses of recent literature (see below), we
treated her with IVIG: 400 mg/kg per day for 5 days.
Treatment was tolerated well and had a pronounced positive
effect on clinical symptoms. Within several days, her
mobility increased, and she was no longer wheelchair
bound. Within 1 week, the SC disappeared fully. A
prophylactic regimen of penicillin was administered, and
in a follow-up period of 2 years, no relapse of the disease
occurred.
Patient number 2, a 13-year-old girl, was referred to us
by her physiotherapist because of dysarthria, ataxia and
balance problems. This child was initially referred for
physiotherapy because of chronic fatigue.
At referral, the complaints existed for 2 weeks and were
slowly progressive. She had severe balance difficulties,
made involuntary movements with her mouth and tongue
and suffered from general muscle weakness. A month
before, she had been diagnosed with pneumonia for which
her general practitioner had treated her with amoxicillin/
clavulanate.
On physical examination, the patient made involuntary
oral movements smacking her lips and moving her tongue
in and out of her mouth. Examination of the larger muscle
groups did not show evident muscle weakness. Her reflexes
were normal, but her coordination was slightly abnormal
with a deviant tandem walk. Internal examination revealed
a holosystolic cardiac murmur grade 2/6 with punctum
maximum at the apex.
Additional laboratory research showed a normal blood
cell count, ESR of 29 mm/h and an ASOT of >1,600 IU/ml.
In a throat culture, a group A haemolytic streptococcus was
found. Brain magnetic resonance imaging was normal. A
cardiac ultrasound revealed a mitralis valve insufficiency
without hemodynamic instability.
The patient was given IVIG similarly to patient A. After
administering the drug, the complaints improved substan-
tially. The chorea disappeared completely within days. The
same prophylactic penicillin regimen was used, and for the
corvitium, carbasalate calcium was prescribed. Fatigue
persisted for some weeks. Until now, 2 years later, this girl
also did not have any relapse.
Pathophysiology
The relation between SC and a previous group A
streptococcal (GAS) infection has been established in
1956 [27]. In 1976, Husby et al. discovered in serum of
SC patients that antibodies directed against part of the
GAS bacterium cross-react with neurons of the caudate
nucleus and basal ganglia, a mechanism called molecular
mimicry [12]. Such a pathophysiologic mechanism is also
present in other diseases, for example, in Guillain-Barré
syndrome, where antibodies cross-react with the anti-
ganglioside AB on motor neurones and in idiopathic
thrombocytopenic purpura (ITP) with glycoprotein IIbIIIa
on platelets [21, 26].
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The GAS has two potential epitopes capable of cross-
reactivity. N-acetyl-beta-D-glucosamine (GlcNAc) is a
structural component of the streptococcal cell wall and is
the epitope that actually provokes the antibodies that play a
role in some manifestations of ARF [15, 17]. Several
studies show that GlcNAc cross-reacts with glycoconju-
gates of different molecular composition, for example,
glycoproteins on cardiac valve surface in rheumatic heart
disease. A second molecule called M protein, the major
virulence factor of GAS, turned out to be cross-reactive
with various host α-helical proteins [6, 15].
Bronze and Dale continued to elucidate the pathogenesis
of SC by discovering anti-basal ganglia antibodies (ABGA)
[2]. They demonstrated that rabbits immunised with the
group A M protein produced antiserum that was cross-
reactive with central nerve system antigens in Western
blots. Reactivity to those specific neuronal antigens was
inhibited by pre-incubation with GAS carbohydrate [2]. It
was made clear that these ABGA have a high specificity
and sensitivity [6]. The specific neuronal target antigens in
SC were only recently discovered by Kirvan et al. [14].
They studied human antibodies derived from serum of an
SC patient and found cross-reactivity with intracellular
brain protein tubulin and extracellular lysoganglioside. By
binding to those proteins, a signalling cascade was
triggered that may cause the neurological manifestations
of SC by releasing dopamine to the synapse [14].
Discussion
Textbooks suggest symptomatic treatment for SC with
benzodiazepine, anti-epileptics, phenothiazines or neuro-
leptics. These drugs are central nerve system depressants
and control the main neurological signs of SC. The effect of
these drugs is variable [7, 11, 23].
The pathophysiology of cross-reactive antibodies in SC
implies new treatment options supported by experiences
with immune and inflammatory disorders described above.
Indeed, immune modulating therapy, like corticosteroids or
immunoglobulin infusion, is found to improve SC.
Corticosteroids have been studied most extensively.
There is only one randomised double blind study in which
22 children suffering from SC were treated with 2 mg/kg/
day prednisone during 4 weeks followed by a gradual
discontinuation. On evaluation in weeks8 and 12, these
patients showed a significant reduction in chorea intensity
compared with a 15 patient placebo group [22]. Several
other studies (case reports or retrospective cohorts) dem-
onstrate that prednisone improves the course of the disease
[1, 5, 28]. However, many of these reports note a rapid
relapse of symptoms or the development of important side
effects like Cushing's syndrome and hypertension.
In the past decade, IVIG have been increasingly used in
the treatment of diseases caused by auto-antibodies [13,
31]. The effect is based on the hypothesis that pooled IVIG
may result in the saturation of Fc receptors on phagocytes.
Through competition, they prevent pathogenic auto-
antibodies to bind to these cells and prevent immune
activation [18]. The beneficial effect of IVIG has been
shown in several diseases with molecular mimicry as
underlying pathophysiology. Marked improvement with
this regimen is made in Guillain-Barré syndrome, chronic
inflammatory demyelinating polyneuropathy and ITP [13,
31]. Doses vary from 0.4 g/kg/day for 3–7 days in Guillain-
Barré to 1 g/kg in single dose in ITP [19].
When scrutinising the literature, one randomised con-
trolled clinical trial was found. Eighteen subjects were
entered into this trial, which was designed to determine if
IVIG or plasma exchange would be superior to prednisone
in decreasing severity of chorea. Four patients were
randomised to receive IVIG, eight received plasma ex-
change and six, prednisone. Mean chorea severity was
significantly lower for the entire group at the 1-month
follow-up evaluation, with an overall improvement in half
of them. The between-group differences were not statisti-
cally significant due to small patient numbers. Neverthe-
less, clinical signs improved more rapidly and robustly in
the IVIG and plasma exchange group than in the predni-
sone group [10].
Conclusion
SC is a rare but very disabling manifestation of ARF.
Therapeutic treatment options are still in experimental
stage. Based on pathophysiology and experiences in
comparable diseases, IVIG seems a reasonable treatment
option. This double case report on two SC patients indicates
that IVIG is an effective treatment, although larger studies
are needed to confirm this conclusion.
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